O-Xylene

O-Xylene

SCHEMBL6364677

Cc1ccccc1C.N.O=S(=O)(O)O

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

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

The experimentally established mechanism targets of O-Xylene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.59
ACHE P22303 2/20 0.59
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 5/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
HPGD P15428 3/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CA7 P43166 1/20 0.39
MYC P01106 1/20 0.39
CA12 O43570 1/20 0.39
TDP1 Q9NUW8 3/20 0.38
KDM4E B2RXH2 3/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 2/20 0.38
GMNN O75496 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
O-Xylene SCHEMBL6364680 1.00 TSHR (0.59) TSHRACHESMN1; SMN2ALDH1A1NPC1
O-Xylene SCHEMBL29725142 0.97 TSHR (0.62) TSHRACHESMN1; SMN2ALDH1A1NPC1
O-Xylene SCHEMBL6155104 0.97 TSHR (0.62) TSHRACHESMN1; SMN2ALDH1A1NPC1
O-Xylene SCHEMBL28085642 0.97 TSHR (0.62) TSHRACHESMN1; SMN2ALDH1A1NPC1
O-Xylene SCHEMBL28471142 0.94 TSHR (0.59) TSHRACHESMN1; SMN2ALDH1A1NPC1
O-Xylene SCHEMBL10476945 0.94 TSHR (0.59) TSHRACHESMN1; SMN2ALDH1A1NPC1
O-Xylene SCHEMBL3381229 0.94 TSHR (0.59) TSHRACHESMN1; SMN2ALDH1A1NPC1
O-Xylene SCHEMBL28038086 0.94 TSHR (0.59) TSHRACHESMN1; SMN2ALDH1A1NPC1
O-Xylene SCHEMBL28038085 0.94 TSHR (0.59) TSHRACHESMN1; SMN2ALDH1A1NPC1
O-Xylene SCHEMBL11776221 0.86 TSHR (0.56) TSHRACHESMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1583516-A2 PERSONAL CARE COMPOSITION CONTAINING A CATIONIC CELLULOSE POLYMER AND AN ANIONIC SURFACTANT SYSTEM THE PROCTER & GAMBLE COMPANY (US) 2005-10-12 EP disclosed
WO-2004064802-A2 PERSONAL CARE COMPOSITION CONTAINING A CATIONIC CELLULOSE POLYMER AND AN ANIONIC SURFACTANT SYSTEM THE PROCTER & GAMBLE COMPANY (US) 2004-08-05 WO disclosed
US-6703007-B2 ACTIVATED POLYPEPTIDES; COSMETIC FOR HAIR, SKIN THE PROCTER & GAMBLE COMPANY 2004-03-09 US disclosed
CN-1433297-A Topical compositions comprising protected functional thiols PROCTER & GAMBLE (US) 2003-07-30 CN disclosed
US-6544499-B1 Polysiloxane or silicone resin, a linker, and a molecular hook for treating amino acid based substrates; hair care THE PROCTER & GAMBLE COMPANY 2003-04-08 US disclosed
US-20020041855-A1 TOPICAL COMPOSITIONS COMPRISING FUNCTIONAL NUCLEOPHILES PROTECTED BY PHOSPHORUS-CONTAINING MOIETIES THE PROCTER & GAMBLE COMPANY 2002-04-11 US disclosed
CN-1342065-A Topical compositions comprising functional nucleophiles protected by phosphorus-containing moieties PROCTER & GAMBLE (US) 2002-03-27 CN disclosed
US-20020012639-A1 May be used in hair care, textile care, cosmetics, oral care formulations, skin, nail, laundry, acne care formulations PROCTER & GAMBLE COMPANY, THE 2002-01-31 US disclosed
EP-1143916-A2 TOPICAL COMPOSITIONS COMPRISING PROTECTED FUNCTIONAL THIOLS THE PROCTER & GAMBLE COMPANY (US) 2001-10-17 EP disclosed
EP-1139983-A2 TOPICAL COMPOSITIONS COMPRISING FUNCTIONAL NUCLEOPHILES PROTECTED BY PHOSPHORUS-CONTAINING MOIETIES THE PROCTER & GAMBLE COMPANY (US) 2001-10-10 EP disclosed
WO-2000040210-A2 TOPICAL COMPOSITIONS COMPRISING PROTECTED FUNCTIONAL THIOLS THE PROCTER & GAMBLE COMPANY (US) 2000-07-13 WO disclosed
WO-2000040209-A2 TOPICAL COMPOSITIONS COMPRISING FUNCTIONAL NUCLEOPHILES PROTECTED BY PHOSPHORUS-CONTAINING MOIETIES THE PROCTER & GAMBLE COMPANY (US) 2000-07-13 WO disclosed
EP-0708632-B1 HIGH LATHERING ANTI-DANDRUFF SHAMPOOS PROCTER & GAMBLE (US) 1998-09-30 EP disclosed
CN-1130862-A High lathering anti-dandruff shampoos with improved deposition of particulate anti-dandruff agent PROCTER & GAMBLE (US) 1996-09-11 CN disclosed
EP-0708632-A1 HIGH LATHERING ANTI-DANDRUFF SHAMPOOS THE PROCTER & GAMBLE COMPANY (US) 1996-05-01 EP disclosed
WO-1995002389-A2 HIGH LATHERING ANTI-DANDRUFF SHAMPOOS THE PROCTER & GAMBLE COMPANY (US) 1995-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020041855-A1 TOPICAL COMPOSITIONS COMPRISING FUNCTIONAL NUCLEOPHILES PROTECTED BY PHOSPHORUS-CONTAINING MOIETIES PNISR, NUP205, POLR1C TSHR 1364/4885ACHE 2616/4885SMN1; SMN2 4072/4885
US-20020012639-A1 May be used in hair care, textile care, cosmetics, oral care formulations, skin, nail, laundry, acne care formulations SCLY, TST, SRR TSHR 235/4885ACHE 3335/4885SMN1; SMN2 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.